SPRY deserves a closer look. Shares of ARS Pharmaceuticals are in focus today as the company's innovative needle-free epinephrine spray, Neffy, continues to gain traction in the market. SPRY is up 0.45% as investors react to positive sales data and expansion prospects for its flagship product.
Recent reports highlight Neffy's strong Q3 2025 sales, reaching $31.3 million. This rapid growth suggests that the convenient delivery mechanism of a nasal spray is resonating well with patients who require epinephrine for anaphylaxis. The traditional method of epinephrine injection can be intimidating and prone to user error, making Neffy a potentially game-changing alternative. The simpler administration method could unlock a significant portion of the diagnosed-but-untreated anaphylaxis demographic, further driving sales.
The bullish sentiment surrounding SPRY is fueled by the anticipation of continued sales growth and the potential for global expansion. If Neffy can successfully penetrate international markets, the company's revenue could see a substantial boost. The convenience and ease of use offered by Neffy position it favorably against traditional epinephrine injections, potentially capturing a larger market share.
Sam Rivera is a senior market strategist at Stock Expert AI, covering the biggest market movers and daily stock picks. Sam combines fundamental analysis with market sentiment to deliver actionable insights for retail investors.
Neffy is a needle-free epinephrine nasal spray developed by ARS Pharmaceuticals (SPRY) for the treatment of anaphylaxis. It offers a convenient alternative to traditional epinephrine injections, potentially making it easier for patients to administer the medication during an allergic reaction. The spray delivers epinephrine directly through the nasal passages.
Why is SPRY stock price increasing?
SPRY stock is up due to strong sales of Neffy. Investors are reacting positively to the rapid growth in Neffy sales and the potential for global expansion. The ease of use and convenience of Neffy are attracting patients and could lead to increased market share and revenue for ARS Pharmaceuticals.
